The company has established a strict and standardized quality control organization and a perfect quality assurance system while establishing a strong pharmaceutical R&D and production capacity. It is one of the first GMP certified enterprises of the US Food and Drug Administration. Among them, non-sterile APIs (fermentation, chemical synthesis), sterile APIs and various preparations have passed the certification of national drug regulatory agencies such as US Food and Drug Administration (USFDA), European Drug Quality Committee (EDQM) and South African Drug Administration Committee (MCC).
Qilu Pharmaceutical has a professional marketing team, attaches great importance to the academic promotion and brand building of products, and has established a wide-ranging win-win cooperation relationship. In recent years, anti-infection, anti-tumor, cardiovascular and cerebrovascular products have been highly recognized by clinical users, and the market share of products has continued to increase rapidly. Besides having a nationwide sales network, the company also actively expands the international market, and its products are exported to Europe, North America, South America and Southeast Asia.
The company has successfully developed nearly 100 national-level new drugs, such as Poly-Hutchison, Dobutamine, Shen Jie and Bangda, which provide a wide range of effective drugs for the treatment of major diseases that endanger health. The company's research has won national and provincial scientific and technological progress awards and created good social benefits.
Since 1992, Qilu Pharmaceutical has successively won the honorary titles of "Top 50 Pharmaceutical Industries in China", "Top 500 Pharmaceutical Industries in China 100", "Top 500 Industrial Enterprises with Best Economic Benefits in China", "Top High-tech Enterprises in China 100" and "National May 1 Labor Award". In 2006, it was jointly recognized as "National Enterprise Technology Center" by the National Development and Reform Commission and other five ministries and commissions, and was named as "the first top 500 competitive enterprises of China Enterprise Group" by the National Bureau of Statistics. It is one of the top ten pharmaceutical enterprises with the most growth, and one of the top 100 innovative pharmaceutical enterprises in China in 2006.
Qilu pharmaceutical factory has a workshop built according to GMP standards and a modern high-rise warehouse. It has automatic production lines and quality inspection equipment for powder injection, water injection, tablets, capsules and freeze-dried raw materials. , imported from Spain, Germany, Italy and the United States, established a complete total quality management system, effectively guaranteed product quality and won a good reputation in society.
Qilu pharmaceutical factory bravely entered the high-tech field, invested more than 30 million yuan to set up a biotechnology drug research and development center, the main equipment was imported from abroad, reaching the leading level of domestic genetic engineering drug research and development and production, and passed the national GMP certification at one time. The recombinant human granulocyte colony stimulating factor (Bai Rui), a genetic engineering drug, was put into production ahead of schedule, with good uniformity and stable quality, and was identified as the national G-CSF reference standard collaborative calibration unit by China Institute for the Control of Pharmaceutical and Biological Products. Many other genetically engineered drugs are being actively developed.
Qilu Pharmaceutical Factory also attaches great importance to the development of export-oriented economy, and invested more than 35 million US dollars to establish Qilu-Antibi Pharmaceutical Co., Ltd. with the world-famous Italian Antibi Group, with an annual output of 200 tons of cephalosporin series antibiotic raw materials, which is the largest cephalosporin raw materials manufacturer in China.
Qilu Pharmaceutical Factory has always adhered to the principle that science and technology are the primary productive forces, continuously increased investment in science and technology, and established a "provincial enterprise technology development center". Its speed and level of new drug research and development are in the forefront of the same industry in China. Every year, the national new drug research and development is successful, forming a virtuous circle of "production generation, development generation and reserve generation", laying a solid foundation for the development of enterprises.
Today, Qilu Pharmaceutical Factory is making continuous progress in the new century with a high-spirited attitude and riding the east wind of state-owned enterprise reform. Qilu Pharmaceutical Factory is willing to carry out extensive and various forms of all-round cooperation with universities, scientific research and medical units, go hand in hand and seek common development, and strive to make greater contributions to revitalizing the national pharmaceutical industry and human health!